CJC-1295 no DAC & Ipamorelin 2026: Research, Dosing Evidence, and Buying Criteria

CJC-1295 no DAC (also called Modified GRF 1-29) and Ipamorelin are research use only peptides studied as growth hormone secretagogues that act on two separate pituitary receptor systems: CJC-1295 no DAC at the growth hormone-releasing hormone (GHRH) receptor, and Ipamorelin at the growth hormone secretagogue receptor GHS-R1a. If you arrived searching for CJC-1295 no DAC and Ipamorelin 2026 research, dosing and buying information, here is the direct answer to all three parts. Research: the receptor-level pharmacology of each peptide class is reasonably well characterised in preclinical work, while published human data on the two compounds administered together is thin. Dosing: no quantities are reproduced on this page, because the material surveyed for this article carries no citable, verifiable source for them, and these compounds are supplied for laboratory research and are not for human use. Buying: what is actually verifiable at the point of purchase is documentation — batch-specific HPLC purity data, endotoxin testing results, and documented cold chain handling — which the sourcing section below covers in detail.

That "no figures" answer is deliberate rather than evasive. The microgram quantities circulated for this pair trace back to community write-ups rather than to indexed trials, and this article does not repeat a number it cannot source; where the literature is silent, this page states that the literature does not specify it. What can be described honestly is mechanism. CJC-1295 no DAC is a GHRH analogue that engages somatotroph GHRH receptors; Ipamorelin is a pentapeptide ghrelin mimetic that engages GHS-R1a. The rationale for studying them together — two receptor pathways converging on the same secretory cell population — is mechanistic reasoning drawn from general GHRH and ghrelin-receptor pharmacology, and it is labelled as such here rather than presented as a demonstrated outcome from a trial of the combination.

Our team has worked with research institutions across multiple continents sourcing peptides for GH pulse studies, mitochondrial function trials, and metabolic intervention research. The difference between a well-constructed sourcing decision and a poor one comes down to understanding receptor dynamics, the distinction between pulsatile and continuous receptor exposure, and the source verification methods most guides skip entirely.

What does the evidence actually establish about CJC-1295 no DAC and Ipamorelin in 2026?

It establishes a mechanistic contrast rather than a validated regimen. The most consequential distinction in this compound pair is the DAC designation itself. CJC-1295 WITH DAC carries a drug affinity complex engineered to bind albumin covalently, which extends circulating exposure into the range of days and produces a flatter, sustained pattern of GH availability. The "no DAC" form lacks that complex and clears far faster — commonly described as on the order of thirty minutes of functional activity — so its influence on the pituitary is transient rather than continuous. These are properties of the molecular design as reported in peptide chemistry references and supplier documentation, not findings this article can attach to a specific indexed trial, and the precise human pharmacokinetic profile of either form is not specified in the literature available for this page.

Why the designation matters is a receptor-pharmacology argument, and it should be read as mechanistic reasoning rather than as compound-specific evidence. Endogenous growth hormone is secreted in pulses, and G-protein-coupled receptors in general show desensitisation and downregulation under sustained agonist occupancy. A short-acting GHRH analogue overlaps with existing secretory episodes and then clears; a long-acting one does not. How quickly desensitisation occurs with the DAC variant, at what exposure, and whether the no-DAC form avoids it entirely are questions the sources reviewed for this article do not answer with citable human data.

This article covers the receptor mechanisms that differentiate CJC-1295 no DAC from the DAC variant, what the literature does and does not specify about administration intervals and stability, the sourcing criteria that separate documented research-grade peptide from undocumented material, and the evidence gaps that researchers designing GH-secretion studies should account for before committing to a study design.

CJC-1295 no DAC Mechanism: GHRH Receptor Dynamics Beyond Half-Life

CJC-1295 without DAC (also called Modified GRF 1-29 or Mod GRF) is a 29-amino-acid synthetic analogue of growth hormone-releasing hormone. The structural modifications — substitutions at positions 2, 8, 15 and 27 — are designed to confer resistance to dipeptidyl peptidase-IV (DPP-IV) cleavage, the enzymatic step that clears native GHRH within minutes of release. The intent of the design is a molecule that survives long enough to reach anterior pituitary GHRH receptors at meaningful concentrations while still clearing between endogenous secretory episodes. The exact duration of that window in humans is not specified in the literature available for this article.

The receptor mechanism is better characterised than the kinetics, and it is general somatotroph physiology rather than a CJC-1295-specific finding. GHRH receptors are G-protein-coupled receptors of the Gs subtype: agonist binding activates adenylyl cyclase, raises intracellular cAMP, and triggers calcium influx in somatotroph cells, and that calcium-dependent exocytosis releases stored GH granules. What is compound-specific is that Modified GRF 1-29 retains the GHRH(1-29) active fragment, which is the region responsible for engaging that receptor; the DPP-IV-resistant substitutions sit outside the core binding determinants. Claims that the analogue binds with a specific fold-increase in affinity over native GHRH appear widely online, but no sourceable figure is available for this page, so none is reproduced.

What can be described about timing is physiology, not instruction. Endogenous GH secretion is episodic, with a prominent nocturnal episode following sleep onset and further episodes associated with fasted states. A short-acting GHRH analogue is studied on the premise that it can overlap with those endogenous episodes rather than replace them. Whether that premise holds for CJC-1295 no DAC in humans, and over what period of repeated exposure, is an open question in the sources reviewed here; the honest position is that the preclinical and mechanistic case is stronger than the human evidence.

Ipamorelin: Selective Ghrelin Receptor Agonism and What Selectivity Means

Ipamorelin is a pentapeptide ghrelin mimetic described in the preclinical pharmacology literature as selective for the GHS-R1a (growth hormone secretagogue receptor 1a) subtype. The comparison that matters is with earlier-generation secretagogues — GHRP-2, GHRP-6, Hexarelin — which are characterised as producing measurable ACTH/cortisol and prolactin responses alongside GH release. Ipamorelin is characterised as producing substantially less of that off-target endocrine activity. This is receptor-binding and preclinical characterisation, clearly labelled as such; the specific cross-reactivity percentages and the concentration multiples at which they were measured are not specified in the literature available for this article, so no numbers are given.

The practical implication for study design, stated at the mechanism level rather than as an outcome, is that a secretagogue with less cortisol and prolactin spillover isolates the GH pathway more cleanly. Research programmes examining mitochondrial biogenesis, muscle protein synthesis signalling, or lipolytic pathway activity have to separate GH-driven effects from glucocorticoid-driven ones; an agent with a narrower endocrine footprint reduces that confound. Human trial data on Ipamorelin is thin relative to the volume of mechanistic discussion it attracts, and that asymmetry should be stated plainly rather than papered over.

Ipamorelin's described kinetic signature is a sharp secretory episode that rises shortly after administration and returns toward baseline within a couple of hours, which is the profile that makes it a candidate for pairing with a short-acting GHRH analogue. Combined with GHRH-receptor engagement from CJC-1295 no DAC, the two-pathway model predicts a larger secretory episode than either agent alone. That prediction is mechanistic reasoning based on how the two receptor systems interact in somatotroph physiology; this page does not attach a magnitude to it, because no citable measurement of the combination is available here.

Administration Intervals, Formulation and Stability: What the Literature Does and Does Not Specify

The question researchers ask most often is about intervals: how far apart exposures need to be to preserve a pulsatile pattern rather than a continuous one. The sources reviewed for this article do not specify a validated interval for CJC-1295 no DAC and Ipamorelin, individually or in combination. What is available is the general principle that pulsatile receptor engagement and continuous receptor engagement are pharmacologically different situations, and that the no-DAC form was designed for the former. Any specific interval presented elsewhere as authoritative should be traced to its source before it is relied on in a study design.

Formulation is more concrete. Both peptides are supplied as lyophilised powders, a format used across peptide chemistry because dried protein is markedly more stable than protein in solution. General peptide stability science describes solution-phase peptides as susceptible to hydrolysis, oxidation and aggregation, with degradation rates rising as temperature rises; aggregation is the process that turns a clear solution cloudy. These are general properties of peptides in solution rather than measurements specific to CJC-1295 no DAC or Ipamorelin, and the specific stability limits for these two compounds — hold times, excursion tolerances, potency loss at given temperatures — are not specified in the literature available here. Because this material is research use only and not for human use, this page describes those stability principles rather than issuing handling or preparation steps.

What a supplier can be held to is documentation. Real Peptides uses small-batch synthesis with exact amino-acid sequencing and supplies batch-specific analytical documentation with each order, so that the purity of the material entering a study is a known quantity rather than an assumption. Cold chain handling from synthesis through delivery is the other half of that chain: analytical purity measured at the point of synthesis says nothing about the condition of material that spent a week above its storage temperature in transit.

CJC-1295 no DAC vs Ipamorelin vs the DAC Variant: Research Comparison

What If: CJC-1295 no DAC and Ipamorelin Research Scenarios

What If Material Is Exposed to a Temperature Excursion?

General peptide chemistry describes elevated temperature as an accelerant of degradation pathways including hydrolysis, oxidation and aggregation, with solution-phase peptide more vulnerable than lyophilised powder. The consequence described in that general literature is loss of intact peptide and the appearance of related-substance impurities, which is why analytical purity is measured on the batch rather than assumed. The magnitude of loss for CJC-1295 no DAC or Ipamorelin at a specific temperature and duration is not specified in the literature available for this article, and no figure is estimated here.

What If a Reconstituted Solution Appears Cloudy or Contains Particulates?

In peptide analytical chemistry, turbidity and visible particulates in a previously clear solution are described as indicators of protein aggregation or of particulate contamination. Aggregated peptide is structurally altered material, which is why aggregation is tracked as a stability-indicating attribute in formulation science generally. This is general peptide science rather than a compound-specific finding for this pair, and the conditions under which these two specific peptides aggregate are not specified in the sources reviewed.

What If Receptor Exposure Becomes Continuous Rather Than Pulsatile?

This is the core pharmacological question behind the DAC versus no-DAC distinction, and the answer available is mechanistic. G-protein-coupled receptors, including the GHRH receptor, are described in general receptor pharmacology as undergoing desensitisation and downregulation under sustained agonist occupancy, whereas intermittent occupancy allows resensitisation between episodes. Extending that principle to CJC-1295 no DAC and Ipamorelin specifically is reasoning by mechanism; the available literature does not specify at what exposure or over what timeframe desensitisation occurs with either compound.

What Sourcing and Purity Verification Actually Mean When You Buy

The candid position on sourcing is that the peptide market operates with limited regulatory oversight outside registered compounding and pharmaceutical facilities, and that material sold under a research-grade label varies in what has actually been measured on it. Claims circulating about the proportion of vendors selling under-purity product are frequently quoted without a traceable source; this article does not reproduce those figures, because no verifiable citation for them is available here. What can be stated without invention is that purity and endotoxin status are measurable properties, and that a batch which has not been measured is a batch of unknown composition.

Verification therefore rests on three documents rather than on marketing language: a batch-specific HPLC certificate of analysis with the measured purity and the retention time corresponding to the target peptide; endotoxin testing with the measured result disclosed rather than merely asserted; and verifiable cold chain logistics from synthesis through delivery. Real Peptides provides batch-specific HPLC and mass spectrometry documentation with every order for exactly this reason. Purity is not a linear proxy for performance in a study — the remainder of an imperfect batch is synthesis by-product, which may include truncated sequences or oxidised residues, and those by-products are an uncontrolled variable in any experiment built on that material.

The bottom line for a buying decision is procedural, not promissory: if a supplier declines to provide third-party analytical documentation or ships without temperature-controlled logistics, the composition of what arrives is unverified. For researchers designing trials around GH secretion kinetics, that unverified composition is the variable most likely to make results irreproducible, and it is the one variable entirely within the purchaser's control.

Understanding the receptor dynamics, the pulsatile-versus-sustained exposure distinction, and the sourcing verification standards behind CJC-1295 no DAC and Ipamorelin research is what separates a defensible study design from wasted material. The two-pathway model is coherent at the mechanism level; the human evidence for the combination is thin, and this page has said so rather than filling the gap with unsourced numbers. If you are designing metabolic intervention studies, mitochondrial biogenesis trials, or GH pulse characterisation research, verifying analytical documentation before committing to a study design is the step that protects the data. Explore our high-purity research peptides including the CJC-1295 and Ipamorelin blend, supplied with third-party purity certification and verified cold chain delivery for laboratory research use only.

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

1. Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
2. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
3. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
4. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
5. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
6. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
7. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286